Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2021 | 1 |
2023 | 2 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean
xia chen ai
(61 results)?
Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer.
Oncologist. 2023 Oct 3;28(10):866-874. doi: 10.1093/oncolo/oyad209.
Oncologist. 2023.
PMID: 37487056
Free PMC article.
RESULTS: Of 270 eligible patients, 127 (median age 64 years) were treated with palbociclib + AI, and 143 (median age 68 years) were treated with an AI. Median follow-up was 24.0 months for palbociclib + AI and 18.2 months for AI-treated patients. ...Me …
RESULTS: Of 270 eligible patients, 127 (median age 64 years) were treated with palbociclib + AI, and 143 (median age 68 years) were t …
Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer.
Engel-Nitz NM, Johnson MG, Johnson MP, Cha-Silva AS, Kurosky SK, Liu X.
Engel-Nitz NM, et al.
Patient Prefer Adherence. 2023 Apr 18;17:1049-1062. doi: 10.2147/PPA.S401480. eCollection 2023.
Patient Prefer Adherence. 2023.
PMID: 37096162
Free PMC article.
Adult patients with mBC who had continuous enrollment 12 months prior to mBC diagnosis and initiated first-line palbociclib with aromatase inhibitor (AI) or fulvestrant between 02/03/2015 and 12/31/2019 were included. ...RESULTS: Patients (n = 1066) with a mean age of 66 y …
Adult patients with mBC who had continuous enrollment 12 months prior to mBC diagnosis and initiated first-line palbociclib with aromatase i …
Item in Clipboard
Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
Brufsky A, Liu X, Li B, McRoy L, Layman RM.
Brufsky A, et al.
Target Oncol. 2021 Sep;16(5):601-611. doi: 10.1007/s11523-021-00826-1. Epub 2021 Aug 2.
Target Oncol. 2021.
PMID: 34338965
Free PMC article.
BACKGROUND: Limited information exists regarding tumor response to palbociclib plus an aromatase inhibitor (AI) versus AI alone in real-world practice. OBJECTIVE: To evaluate the real-world tumor response of palbociclib plus letrozole (PAL+LET) versus LET alone as f …
BACKGROUND: Limited information exists regarding tumor response to palbociclib plus an aromatase inhibitor (AI) versus AI alon …
Item in Clipboard
Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling.
Maculaitis MC, Liu X, Will O, Hanson M, McRoy L, Berk A, Crastnopol M.
Maculaitis MC, et al.
Patient Prefer Adherence. 2020 Nov 5;14:2201-2214. doi: 10.2147/PPA.S254934. eCollection 2020.
Patient Prefer Adherence. 2020.
PMID: 33177814
Free PMC article.
PURPOSE: To understand and compare preferences for dosing- and toxicity-related attributes associated with selective cyclin-dependent 4/6 kinase inhibitors regimens among US oncologists and patients. MATERIALS AND METHODS: Oncologists and patients with mBC participated in …
PURPOSE: To understand and compare preferences for dosing- and toxicity-related attributes associated with selective cyclin-dependent 4/6 ki …
Item in Clipboard
Cite
Cite